SCHEMBL4296583

SCHEMBL4296583

O=C(O)N1CCN(C(c2ccccc2)(c2ccccc2)c2ccccc2)[C@H](CO)C1

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TACR1 P25103 1/20 0.37
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
CHRM3 P20309 5/20 0.34
CHRM1 P11229 4/20 0.34
ALDH1A1 P00352 3/20 0.34
CHRM4 P08173 1/20 0.34
CHRM5 P08912 1/20 0.34
TSHR P16473 1/20 0.34
MAPK1 P28482 1/20 0.34
GAA P10253 1/20 0.34
ME2 P23368 1/20 0.33
ME1 P48163 1/20 0.33
ME3 Q16798 1/20 0.33
LMNA P02545 1/20 0.33
TEAD1 P28347 1/20 0.33
TEAD3 Q99594 1/20 0.33
CHRM2 P08172 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13705281 0.82 SMN1; SMN2 (0.49) MEN1KMT2A
SCHEMBL4290185 0.80 TEAD1 (0.35) MEN1KMT2ACHRM3CHRM1ALDH1A1
SCHEMBL23415503 0.80 LMNA (0.34) MEN1KMT2ACHRM3CHRM1ALDH1A1
SCHEMBL3907228 0.80 LMNA (0.34) MEN1KMT2ACHRM3CHRM1ALDH1A1
SCHEMBL20595815 0.77 MEN1 (0.38) MEN1KMT2ACHRM3CHRM1CHRM4
SCHEMBL29182442 0.77 MEN1 (0.38) MEN1KMT2ACHRM3CHRM1CHRM4
SCHEMBL25338317 0.77 MEN1 (0.38) MEN1KMT2ACHRM3CHRM1CHRM4
SCHEMBL4285893 0.76 GAA (0.38) MEN1KMT2ATSHRMAPK1GAA
SCHEMBL4288482 0.76 USP2 (0.41) MEN1KMT2ACHRM1ALDH1A1TSHR
SCHEMBL29104081 0.75 HTT (0.35) TACR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090227560-A1 Substituted imidazole compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-09-10 US disclosed
US-20090156612-A1 Substituted imidazole compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-18 US disclosed
WO-2008139941-A1 SUBSTITUTED IMIDAZOLE COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-11-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156612-A1 Substituted imidazole compound and use thereof REN, ACE, AGT TACR1 97/4885MEN1 1254/4885KMT2A 1049/4885
US-20090227560-A1 Substituted imidazole compound and use thereof REN, ACE, AGT TACR1 97/4885MEN1 1254/4885KMT2A 1049/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.